



**HAL**  
open science

## **Engineering GPCR signaling pathways with RASSLs**

Bruce R Conklin, Edward C Hsiao, Sylvie Claeysen, Aline Dumuis, Supriya Srinivasan, John R Forsayeth, Jean-Marc Guettier, Wei Chun Chang, Ying Pei, Ken D Mccarthy, et al.

► **To cite this version:**

Bruce R Conklin, Edward C Hsiao, Sylvie Claeysen, Aline Dumuis, Supriya Srinivasan, et al..  
Engineering GPCR signaling pathways with RASSLs. *Nature Methods*, 2008, 5 (8), pp.673-678.  
10.1038/nmeth.1232 . hal-02483728

**HAL Id: hal-02483728**

**<https://hal.science/hal-02483728v1>**

Submitted on 18 Feb 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Published in final edited form as:

Nat Methods. 2008 August ; 5(8): 673–678. doi:10.1038/nmeth.1232.

## Engineering GPCR signaling pathways with RASSLs

Bruce R. Conklin<sup>1,2,\*</sup>, Edward C. Hsiao<sup>1,2,3</sup>, Sylvie Claeysen<sup>4</sup>, Aline Dumuis<sup>4</sup>, Supriya Srinivasan<sup>5</sup>, John R. Forsayeth<sup>6</sup>, Jean-Marc Guettier<sup>7</sup>, W.C. Chang<sup>1,8</sup>, Ying Pei<sup>9</sup>, Ken D. McCarthy<sup>9</sup>, Robert A. Nissenson<sup>1,3</sup>, Jürgen Wess<sup>7</sup>, Joël Bockaert<sup>4</sup>, and Bryan L. Roth<sup>9,\*</sup>

<sup>1</sup>Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158

<sup>2</sup>Departments of Medicine and of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94143

<sup>3</sup>Endocrine Research Unit, VA Medical Center, and Departments of Medicine and Physiology, University of California, San Francisco, CA 94121

<sup>4</sup>CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier, France and INSERM, U661, Montpellier, France and Université Montpellier, Montpellier, France

<sup>5</sup>Department of Physiology, University of California, San Francisco, CA 94158

<sup>6</sup>Department of Neurosurgery, University of California, San Francisco, CA 94103

<sup>7</sup>Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, MD 20892

<sup>8</sup>Graduate Program in Pharmaceutical Sciences and Pharmacogenomics, University of California, San Francisco, CA 94158

<sup>9</sup>Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599

### Abstract

We are creating families of designer G-protein-coupled receptors (GPCRs) to allow for precise spatiotemporal control of GPCR signaling *in vivo*. These engineered GPCRs, called receptors activated solely by synthetic ligands (RASSLs), are unresponsive to endogenous ligands but can be activated by nanomolar concentrations of pharmacologically inert, drug-like small molecules. Currently, RASSLs exist for the three major GPCR signaling pathways (G<sub>s</sub>, G<sub>i</sub>, G<sub>q</sub>). These new advances are reviewed here to help facilitate the use of these powerful and diverse tools.

G-protein-coupled receptors (GPCRs) are an ideal vehicle for engineering synthetic signaling systems. These receptors function as signaling switches throughout the body and regulate virtually every physiological response<sup>1-3</sup>. GPCRs are also the largest gene family targeted for drug discovery<sup>4</sup>. GPCRs stimulate a variety of G protein pathways; for example, G<sub>s</sub> stimulates

\*To whom correspondence should be addressed Bruce R. Conklin, MD Gladstone Institute of Cardiovascular Disease 1650 Owens Street San Francisco, CA 94158 Tel: (415) 734-2712; Fax: (415) 355-0960 E-mail: E-mail: bconklin@gladstone.ucsf.edu. Bryan L. Roth MD, PhD, Department of Pharmacology CB #7365, UNC Medical School Chapel Hill, NC 27599-7365 919-966-7536 E-mail: bryan\_roth@med.unc.edu.

Highlighted Papers (numbers refer to order in citations) 5. Coward et al., PNAS 1998: First use of the term RASSL and first description of a RASSL that responds to a drug with nanomolar potency allowing potential *in vivo* use.

8. Armbruster et al., PNAS, 2007. First application of directed evolution for engineering RASSLs/DREADDs that respond to an experimentally inert ligand (CNO).

10. Redfern et al., Nature Biotech 1999: First use of a RASSL in a transgenic animal. Expression of hRO-i (previously known as Ro1) in the heart allows control heart rate within seconds after administration of spiradoline.

11. Mueller et al., Nature 2005. First use of a RASSL to decode a sensory pathway *in vivo*. RASSL expression in the sweet or bitter taste buds of transgenic mice allows the RASSL ligand (spiradoline) to induce a sweet (attractive) or bitter (aversive) responses.

cAMP production,  $G_i$  inhibits cAMP production, and  $G_q$  stimulates phospholipase C and releases intracellular calcium stores. Since GPCRs have a relatively simple modular design and are encoded by small genes (usually <1.5 kb), engineered GPCRs can be easily transferred without loss of their functionality into different tissues and species. Finally, designer GPCRs could be useful for regulating physiologic processes and engineering tissues with stem cells and other technologies.

Attempts to engineer GPCRs that are activated solely by pharmacologically inert drug-like molecules have met with varying degrees of success (Table 1). Engineered receptors and engineered receptor/ligand pairs have been created by several approaches and bear different names—receptors activated solely by synthetic ligands (RASSLs)<sup>5</sup>, therapeutic receptor-effector complexes (TREC)s<sup>6</sup>, neoceptors<sup>7</sup>, and designer receptors exclusively activated by designer drugs (DREADDs)<sup>8</sup>. Here we will refer to them as RASSLs, and we propose a consensus nomenclature (Table 1) for those in widespread use or in development. This nomenclature links the name of the parent receptor to the major G-protein signaling pathway activated by the receptor.

## Engineering RASSLs by directed mutagenesis

In the first attempt to make a designer GPCR, Strader and colleagues developed a series of compounds to selectively activate a mutant version of the  $\bullet\bullet$ -adrenergic receptor ( $\bullet\bullet$ -AR) that was unresponsive to its natural hormone<sup>9</sup>. This group focused on D113<sup>3,32</sup>, which is conserved among all biogenic amine GPCRs and is critical for binding terminal amine groups (Fig. 1). Mutating D113<sup>3,32</sup> to Ser greatly reduced activation of the  $\bullet$ 2-AR by biogenic amines. Remarkably, this mutation enabled the newly synthesized butanone derivative, 1-(3',4'-dihydroxyphenyl)-3-methyl-1-butanone (L-185,870), to activate the mutant receptor but not the wildtype (WT) receptor, albeit with relatively low potency ( $EC_{50}=118 \bullet M$ )<sup>9</sup>. Although this original report was inspiring, the synthetic agonist had low affinities and unknown pharmacokinetics that rendered it impractical for *in vivo* use.

The first engineered receptor or RASSL activated by an agonist with nanomolar affinity suitable for *in vivo* use was reported by Coward et al.<sup>5</sup>, who took advantage of potent synthetic drugs originally developed as potential analgesics, such as  $\bullet$ -opioid receptor (KOR) agonists (e.g., spiradoline). The first RASSL was created by introducing mutations in the KOR that abrogated signaling via the natural peptide ligands, yet preserved stimulation by spiradoline<sup>5</sup>. This engineered human RASSL (hRO-i; h=human, R=RASSL, O=Opioid, i= $G_i$ ; referred to as Ro1<sup>5</sup>, a  $G_i$ -coupled receptor, has been expressed in at least six tissues (Fig. 2) in transgenic animals. Diverse phenotypes were induced, including ligand-dependent heart-rate modulation<sup>10</sup>, bitter and sweet taste sensations<sup>11,12</sup>, and ligand-independent cardiomyopathy<sup>13</sup>, hydrocephalus<sup>14</sup>, and osteopenia<sup>15</sup>. These exciting results fueled efforts to develop RASSLs with improved ligand pharmacology and a greater range of signaling responses.

Once scientists understood that RASSLs could be designed to work with existing drugs, new RASSLs soon emerged from studies of a wide variety of receptors, including the 5-HT<sub>4</sub> serotonin<sup>16</sup>,  $\bullet$ 2-adrenergic<sup>6</sup>, H<sub>1</sub>-histamine<sup>17</sup>, A<sub>3</sub> adenosine<sup>7</sup>, 5-HT<sub>2A</sub>-serotonin<sup>18</sup>, and MC4-melanocortin<sup>19</sup> receptors. In most, key residues essential for binding the native ligand were targeted by site-directed mutagenesis. For example, introduction of the D100<sup>3,32</sup>A mutation (analogous to the D113<sup>3,32</sup>A mutation in the  $\bullet$ 2-AR<sup>9</sup>) into the  $G_s$ -coupled human 5-HT<sub>4</sub> serotonin receptor abolished the ability of 5-HT to activate the receptor but did not affect the activity of many synthetic agonists, including carbazimidamides, benzamides, benzimidazolones, and aryl ketones; this RASSL, previously known as Rs1, will be referred to as hRS-s<sup>16</sup>. Many of these synthetic agonists have drug-like properties, nanomolar affinities,

and readily penetrate the central nervous system and can therefore be used effectively *in vivo*<sup>16,20</sup>. In addition, hRS-s is activated by antagonists of the 5-HT<sub>4</sub> receptor, which have fewer *in vivo* side effects than 5-HT<sub>4</sub> receptor agonists. Intriguingly, when expressed in osteoblasts of young mice, hRS-s dramatically alters bone growth *in vivo*<sup>21</sup>, presumably due to constitutive activation of the G<sub>s</sub> pathway. These experiments provide valuable insights into the specific cellular and temporal factors that allow G<sub>s</sub> signaling to induce bone growth.

This same mutagenesis approach of replacing conserved residues of the binding pocket with alanines has been applied to other biogenic amine receptors. Thus, mutation of a conserved serine residue in the fifth transmembrane region (S204<sup>5.46</sup>A) led to a sizeable loss of affinity and efficacy of (-)-adrenaline at  $\alpha_2$ -adrenoceptors (G<sub>i/o</sub>-coupled receptors), while the mutated receptor could still be activated by synthetic agonists (UK14304, clonidine) or even by antagonists of the WT receptor (atipamezole, SKF86466)<sup>22</sup>. Similarly, a G<sub>q/11</sub>-coupled RASSL was obtained by introducing the F435<sup>6.55</sup>A mutation into the histamine H<sub>1</sub> receptor<sup>17</sup>. This RASSL could be activated by high concentrations of endogenous histamine and had improved affinity and potency for 2-phenylhistamines, a class of synthetic H<sub>1</sub>R agonists (2-[3-chlorophenyl]histamine). Interestingly, alternative substitutions at this position (F435<sup>6.55</sup>) resulted in RASSLs with different levels of constitutive activity; F435<sup>6.55</sup>A (hRH-s) had the lowest level of constitutive signaling.

## Creating RASSLs by directed molecular evolution

Despite these noteworthy advances, first-generation RASSLs were not ideal for experimentation. The ligands of first-generation RASSLs activated endogenous receptors (e.g.,  $\mu$ -opioid, H<sub>1</sub>-histamine, 5-HT<sub>4</sub>-serotonin, MC4-melanocortin), and had low affinities for the mutated receptor (A3-adenosine neoeceptor;  $\alpha_2$ -AR TREC; 5-HT<sub>2A</sub> serotonin RASSL). Moreover, profound phenotypes induced by constitutive activity were observed upon RASSL overexpression *in vivo* (RO-i and RS-s). Finally, development of new RASSLs by repeated cycles of directed mutagenesis was labor intensive and did not consistently yield receptors with ideal agonist affinities or controlled levels of constitutive signaling. To overcome these inherent difficulties, we developed a generic approach to create a new class of RASSLs that have low constitutive activity and respond specifically to drug-like, pharmacologically inert small molecules<sup>8</sup>.

We used a well-established yeast mutagenesis system to produce hundreds of thousands of mutant hM<sub>3</sub> muscarinic receptors and screened them for signaling characteristics of an “ideal” RASSL<sup>8</sup>. After multiple rounds of mutagenesis and iterative screening, we isolated mutants that had lost the ability to respond to the natural ligand (acetylcholine) but gained the ability to respond with nanomolar potency to clozapine-*N*-oxide (CNO), a pharmacologically inert, bioavailable<sup>23</sup> synthetic compound (Fig. 3). This new class of RASSLs was designated DREADDs (ref. 6). We will refer to this first DREADD as “hRMD-q” (RASSL M<sub>3</sub> DREADD, G<sub>q</sub>-coupled; referred to as hM3-D in ref. 6). The RMD-q receptor is insensitive to acetylcholine but activates the G<sub>q</sub> pathway to induce calcium mobilization upon binding of CNO. Analogous mutations in the closely related M<sub>4</sub> muscarinic receptor, which is G<sub>i</sub>-coupled and inhibits cAMP accumulation, led to another RASSL/DREADD that we call hRMD-i (referred to as hM4D<sup>8</sup>). Intriguingly, when activated by CNO, hRMD-i silenced hippocampal neurons via G $\alpha$ -mediated activation of G-protein inwardly rectifying K<sup>+</sup> (GIRK) channels<sup>8</sup>. It is likely that hRMD-i will be widely used to induce neuronal silencing *in vivo* via indirect activation of GIRKs. More recently, (Guettier, J.M., et al abstract, International Group on Insulin Secretion, St. Jean Cap-Ferrat, France; 2007), made chimeras of the rat equivalent of the hRMD-q that incorporates the second and third intracellular loops of the G<sub>s</sub>-coupled  $\alpha_1$  adrenergic receptor to create a G<sub>s</sub>-coupled RASSL (rRMD-s, see table 1). Thus, CNO can be used to activate the G<sub>s</sub>, G<sub>i</sub>, or G<sub>q</sub> signaling pathways, depending on which of the new RASSLs is utilized.

With the current DREADD-type RASSLs, only two point mutations were required to create hRMD-I and hRMD-q. By contrast, the rRMD-s required two point mutations and swapping of two intracellular loops. Creating other DREADD-type RASSLs by directed molecular evolution will likely require at least multiple point mutations based on our own unpublished experience (Pei et al, in preparation). Thus far, all of the point mutations have been found in or near predicted binding sites for orthosteric ligands.

The general method we devised evolves GPCR ligand specificity toward pharmacologically “inert” ligands (e.g., drug-like compounds without known molecular targets). This technique is likely to be widely used to create designer GPCRs, owing to the availability of strains of yeast (*Saccharomyces cerevisiae*) engineered to express and respond to human GPCRs<sup>24,25</sup>. When these GPCR-expressing yeast are activated by an agonist, the signal induces the expression of a variety of selectable markers under control of a Fus-1 promoter. This system allows for the facile screening and optimization of millions of mutant GPCRs in a relatively short time<sup>26</sup>. Dozens of human GPCRs have been expressed in yeast<sup>27</sup>, thereby opening up the potential to create families of designer GPCRs activated by specific small molecules.

## RASSLs as molecular switches for tissue engineering

RASSLs may be valuable in controlling growth and ensuring appropriate control of function for experimental or therapeutic tissue engineering. GPCR signaling is essential for the growth and differentiation of many tissues<sup>2</sup>. For example, the 5-HT<sub>2B</sub> serotonin receptor is required for cardiac development and cell-cycle progression<sup>28-30</sup>. Ectopic signaling via GPCRs can promote abnormal growth<sup>3</sup>, leading to human disease. For instance, drug-induced valvular heart disease may be caused by excessive stimulation of cardiac 5-HT<sub>2B</sub> receptors<sup>31</sup>. One can envision the use of RASSLs to activate discrete signaling pathways to promote the proper growth and differentiation of engineered tissues.

Another potential use of RASSLs is to gain precise control of signaling in neurons and other tissues. Currently, this control in defined neuronal populations can be facilitated by expressing RASSLs in a neuron-specific manner. We reported that CNO-mediated activation of the G<sub>i</sub>-coupled hRMD-i induces neuronal silencing when expressed in hippocampal neurons<sup>8</sup>. When expressed in hippocampal neurons, hRMD-q induces neuronal excitation and intracellular Ca<sup>++</sup> release in CNO-dependent fashion (Rogan and Roth, manuscript in preparation). Using these two engineered muscarinic receptors, one could gain precise bi-directional control of neuronal firing *in vitro* and *in vivo*. These modified receptors could also be used in other excitable tissues, such as cardiac pacemaker cells, where G<sub>s</sub> stimulation speeds diastolic depolarization and accelerates heart rate, and G<sub>i</sub> stimulation slows heart rate. Expression of different G<sub>s</sub> (e.g., hRS-s or rRMD-s) and G<sub>i</sub> (e.g., RO-i or hRMD-i) RASSLs in pacemaker cells could allow for the precise regulation of heart rate without affecting cardiac muscle function.

## The importance of constitutive signaling by RASSLs

In studies of first-generation RASSLs expressed *in vivo*, constitutive signaling (constitutive activity) has often produced the most profound effects. Overexpression of a G<sub>i</sub>-coupled RASSL (hRO-i) in cardiomyocytes led to cardiomyopathy<sup>13</sup>, while overexpression in osteoblasts led to osteoporosis<sup>15</sup>. Recently a G<sub>s</sub> RASSL (hRS-s) expressed in osteoblasts induced marked bone growth<sup>15</sup>. Constitutive activity is a common property of native GPCRs<sup>32,33</sup> and is essential for the normal function of certain GPCRs<sup>34</sup>. Therefore, RASSLs with different levels of constitutive activity (high and low) will be needed to recapitulate normal GPCR functions. Because of the potential ligand-independent effects, RASSL expression ideally should be controlled through conditional expression systems (e.g., Tet or Cre). With these systems, a single RASSL transgenic line can be used to drive expression in diverse tissues with tighter



temporal control. The second-generation RASSLs (hRMD-q, hRMD-i, rRMD-s) were created to lack constitutive activity<sup>8</sup>, and thus far, their overexpression in mice has not elicited baseline phenotypes (Rogan, Roth, Guettier and Wess, unpublished observations). These second-generation RASSLs will be most useful for studies in which ligand-dependent effects (rather than baseline phenotypes) are sought.

## Future directions

The RASSL field has undergone dramatic growth in the past decade, but many more challenges lie ahead. For instance, the ideal family of RASSLs would respond to a clinically approved, biologically inert drug (e.g., antibiotic or antiviral) that has no intrinsic effect on human cells, allowing tissue engineering without the drug safety studies needed for relatively new compounds such as CNO. The optimal series of RASSLs would also selectively couple to each of the GPCR pathways, including noncanonical pathways, such as those involving arrestins, GRKs, and intracellular kinases<sup>29</sup>. Furthermore, each RASSL would have different constitutive responses, desensitization properties, and subcellular targeting that could be fine-tuned with simple mutations. For many of these goals, we will need spatiotemporal control of RASSL expression to allow for direct comparisons of RASSL actions that could be applicable to virtually any tissue. Several groups are now testing a variety of approaches (BAC transgenics, knock-ins, and inducible systems) to meet these new challenges and provide new tools to RASSL researchers. With these highly refined tools, biologists will have a better understanding of how to use RASSLs and GPCR signaling pathways for tissue engineering.

The cross-disciplinary nature of RASSL-related research fosters a highly collaborative community that makes protocols, reagents, and transgenic animals publicly available whenever possible. Even though individual members of the RASSL community initially created tools specifically for their own research, the potential uses of these tools go well beyond any individual project. Indeed, precisely because GPCR signaling is important to such a wide swath of biology, it is impossible for us to accurately predict how and where RASSLs will be ultimately used.

We anticipate that our RASSL delivery systems will be deployed for a wide range of tissue engineering applications in neurological disease, pain perception, immunology, bone metabolism, and diabetes. In each case, our efforts will provide enabling technologies to rapidly advance those fields. For instance, in many neurological diseases (e.g., Parkinson's disease), RASSLs may be useful for correcting the imbalance of neural pathways, in a manner that could complement the surgical/electrical approaches in current clinical practice. Similarly, many groups envision using tissue-engineering approaches to study pain perception pathways. RASSLs, which selectively modulate neuronal firing, should be ideal for this application. Although GPCRs are clearly important in bone metabolism, many key receptors signal via multiple pathways and exhibit constitutive signaling. RASSLs allow researchers to stimulate discrete signaling pathways in bone metabolism. Finally, in diabetes, GPCRs play a role in the growth, development, and function of insulin-secreting pancreatic  $\beta$ -cells<sup>35</sup>. Dissecting the precise roles of different G-protein signaling pathways in  $\beta$ -cell function should be of considerable therapeutic interest.

Perhaps most importantly, the use of RASSL technology may shed light on relatively unknown aspects of GPCR signaling. For instance, many researchers are investigating nonclassical signaling responses of GPCRs, such as signaling by  $G_{12/13}$ , arrestins, receptor kinases, regulators of G protein signaling, Wnt receptor signals, and scaffolding proteins<sup>29</sup>. It should be of interest to create two RASSLs that only differ in their ability to activate the arrestin pathways. Expression of these two RASSLs in the same spatial and temporal pattern would then allow determination of the true physiological roles of arrestin signaling.

Some of these non-G-protein signaling pathways could prove essential for robust tissue engineering and for uncovering the pathways responsible for stem cell differentiation. One can envision scenarios in which RASSLs are selectively expressed in different stem cell lineages and then activated (with an exogenous ligand or by overexpression) to determine which pathways are responsible for lineage choices and tissue differentiation.

## ACKNOWLEDGMENTS

We would like to thank our funding agencies and the members of our labs who have contributed to the RASSL projects. In particular, we appreciate support by the US National Institutes of Health; HL60664-07 (BRC), DK072071 (RAN), U19MH82441 (BLR), a NARSAD Distinguished Investigator Award (BLR), the American Heart Association pre-doctoral fellowship program (0415005Y to WCC), and the Veterans Affairs Merit Review Program (to BPH), the California Institute of Regenerative Medicine, Gladstone Institute CIRM Fellowship Program (Grant T2-00003 to ECH). The Gladstone Institutes received support from National Center for Research Resources Grant RR18928-01. The authors thank J. Ng, T. Nguyen, D. Srivastava, R.W. Mahley, H. Zahed, B. Phillips, M. Spindler, G. Howard, and S. Ordway for providing valuable technical assistance and discussions.


## REFERENCES

1. Armbruster BN, Roth BL. Mining the receptorome. *J. Biol. Chem* 2005;280:5129. [PubMed: 15590622]
2. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. *Physiol Rev* 2005;85:1159. [PubMed: 16183910]
3. Spiegel AM, Weinstein LS. Inherited diseases involving G proteins and G protein-coupled receptors. *Annu Rev Med* 2004;55:27. [PubMed: 14746508]
4. Hopkins AL, Groom CR. The druggable genome. *Nat Rev Drug Discov* 2002;1:727. [PubMed: 12209152]
5. Coward P, Wada HG, Falk MS, Chan SD, Meng F, Akil H, Conklin BR. Controlling signaling with a specifically designed Gi-coupled receptor. *Proc Natl Acad Sci U S A* 1998;95:352. [PubMed: 9419379]
6. Small KM, Brown KM, Forbes SL, Liggett SB. Modification of the beta 2-adrenergic receptor to engineer a receptor-effector complex for gene therapy. *J Biol Chem* 2001;276:31596. [PubMed: 11402033]
7. Jacobson KA, Gao ZG, Liang BT. Neoeptors: reengineering GPCRs to recognize tailored ligands. *TRENDS Pharmacol Sci* 2007;Vol.28:111. [PubMed: 17280720]
8. Armbruster BN, Li X, Pausch MH, Herlitz S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc Natl Acad Sci USA* 2007;104:5163. [PubMed: 17360345]
9. Strader CD, Gaffney T, Sugg EE, Candelore MR, Keys R, Patchett AA, Dixon RA. Allele-specific activation of genetically engineered receptors. *J Biol Chem* 1991;266:5. [PubMed: 1670767]
10. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, Conklin BR. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. *Nat Biotechnol* 1999;17:165. [PubMed: 10052353]
11. Mueller KL, Hoon MA, Erlenbach I, Chandrashekar J, Zuker CS, Ryba NJ. The receptors and coding logic for bitter taste. *Nature* 2005;434:225. [PubMed: 15759003]
12. Zhao GQ, Zhang Y, Hoon MA, Chandrashekar J, Erlenbach I, Ryba NJ, Zuker CS. The receptors for mammalian sweet and umami taste. *Cell* 2003;115:255. [PubMed: 14636554]
13. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevicz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. *Proc Natl Acad Sci U S A* 2000;97:4826. [PubMed: 10781088]
14. Sweger EJ, Casper KB, Scarce-Levie K, Conklin BR, McCarthy KD. Development of hydrocephalus in mice expressing the G(i)-coupled GPCR Ro1 RASSL receptor in astrocytes. *J Neurosci* 2007;27:2309. [PubMed: 17329428]

15. Peng J, Bencsik M, Louie A, Lu W, Millard S, Nguyen P, Burghardt A, Majumdar S, Wronski TJ, Halloran B, Conklin BR, Nissenson RA. Conditional Expression of a Gi-coupled Receptor in Osteoblasts Results in Trabecular Osteopenia. *Endocrinology*. 2007
16. Claeysen S, Joubert L, Sebben M, Bockaert J, Dumuis A. A single mutation in the 5-HT<sub>4</sub> receptor (5-HT<sub>4</sub>-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). *J. Biol. Chem* 2003;278:699. [PubMed: 12441358]
17. Bruysters M, Jongejan A, Akdemir A, Bakker RA, Leurs R. A G(q/11)-coupled mutant histamine H (1) receptor F435A activated solely by synthetic ligands (RASSL). *J. Biol. Chem* 2005;280:34741. [PubMed: 16027157]
18. Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA, Roth BL. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT<sub>2A</sub> serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. *J Pharmacol Exp Ther* 2000;293:735. [PubMed: 10869371]
19. Srinivasan S, Santiago P, Lubrano C, Vaisse C, Conklin BR. Engineering the melanocortin-4 receptor to control constitutive and ligand-mediated G(S) signaling in vivo. *PLoS ONE* 2007;2:e668. [PubMed: 17668051]
20. Chang WC, Ng JK, Nguyen T, Pellissier L, Claeysen S, Hsiao EC, Conklin BR. Modifying Ligand-Induced and Constitutive Signaling of the Human 5-HT<sub>4</sub> Receptor. *PLoS ONE* 2007;2
21. Hsiao EC, Boudignon BM, Chang WC, Bencsik M, Peng J, Nguyen TD, Manalac C, Halloran BP, Conklin BR, Nissenson RA. Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. *Proc Natl Acad Sci U S A* 2008;105:1209. [PubMed: 18212126]
22. Pauwels PJ. Unravelling multiple ligand-activation binding sites using RASSL receptors. *Trends Pharmacol Sci* 2003;24:504. [PubMed: 14559400]
23. Bender D, Holschbach M, Stocklin G. Synthesis of n.c.a. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in mice. *Nucl Med Biol* 1994;21:921. [PubMed: 9234345]
24. Pausch MH. G-protein-coupled receptors in *Saccharomyces cerevisiae*: high-throughput screening assays for drug discovery. *Trends Biotechnol* 1997;15:487. [PubMed: 9418303]
25. Dohlgan HG, Thorne J, Caron MG, Lefkowitz RJ. Model systems for the study of seven-transmembrane-segment receptors. *Annu Rev Biochem* 1991;60:653. [PubMed: 1652922]
26. Li B, Scarselli M, Knudsen CD, Kim SK, Jacobson KA, McMillin SM, Wess J. Rapid identification of functionally critical amino acids in a G protein-coupled receptor. *Nat Methods* 2007;4:169. [PubMed: 17206152]
27. Minic J, Sautel M, Salesse R, Pajot-Augy E. Yeast system as a screening tool for pharmacological assessment of g protein coupled receptors. *Curr Med Chem* 2005;12:961. [PubMed: 15853708]
28. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. *J Biol Chem* 2002;277:11441. [PubMed: 11801601]
29. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. *Trends Pharmacol Sci* 2007;28:416. [PubMed: 17644195]
30. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta<sub>2</sub>-adrenergic G protein-coupled receptor. *Science* 2007;318:1258. [PubMed: 17962520]
31. Roth BL. Drugs and valvular heart disease. *N Engl J Med* 2007;356:6. [PubMed: 17202450]
32. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. *Naunyn Schmiedebergs Arch. Pharmacol* 2002;366:381. [PubMed: 12382069]
33. Kenakin T. Efficacy at G-protein-coupled receptors. *Nat Rev Drug Discov* 2002;1:103. [PubMed: 12120091]
34. Srinivasan S, Lubrano-Berthelie C, Govaerts C, Picard F, Santiago P, Conklin BR, Vaisse C. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. *J Clin Invest* 2004;114:1158. [PubMed: 15489963]
35. Winzell MS, Ahren B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. *Pharmacol Ther* 2007;116:437. [PubMed: 17900700]




36. Scearce-Levie K, Lieberman MD, Elliott HH, Conklin BR. Engineered G protein coupled receptors reveal independent regulation of internalization, desensitization and acute signaling. *BMC Biol* 2005;3:3. [PubMed: 15707483]




**Figure 1.** Creating RASSLs by targeted mutagenesis. A conserved residue(s) in the canonical binding pocket of biogenic amine receptors (e.g., adrenergic, serotonin, histamine) is mutated to eliminate the binding and activation of the receptor for the native ligand. A model using the coordinates of the  $\beta$ -adrenergic receptor structure<sup>30</sup> is used to illustrate this. In all biogenic amine GPCRs, the binding pocket is composed of a conserved aspartic acid (D113<sup>3,32</sup> in the  $\beta$ -2-AR model; SIDE VIEW) and conserved aromatic and polar residues (TOP VIEW). Mutation of the highly conserved Asp to Ser (D113S) renders the  $\beta$ -2-AR insensitive to  $\beta$ -AR exogenous and endogenous agonists, such as isoproterenol, epinephrine, and norepinephrine. However, the D113S mutant receptor could be activated by the synthetic ligand L-185, 870. Such a targeted mutagenesis approach was used to create both peptidergic RASSLs (e.g.,  $\mu$ -opioid, MC4-melanocortin) and nonpeptidergic RASSLs (H1-histamine, 5-HT2A serotonin, 5-HT4 serotonin,  $\beta$ -2-adrenergic) (see text for details).

# Tissue-specific Effects of hRO-i, a G<sub>i</sub>-RASSL



**Blue= Constitutive phenotype** **Red = Ligand induced phenotype**

**Figure 2.** Myriad ligand-dependent and -independent phenotypes are induced by tissue-specific expression of a single RASSL. Ligand-induced phenotypes are noted in red; constitutive signaling-induced phenotypes are in blue. Asterisks indicate tissues in which RO1 expression results in embryonic or perinatal lethality. Conditional expression allows RASSL researchers to avoid embryonic lethality and analyze adult phenotypes.



**Figure 3.**

Directed molecular evolution to create novel RASSLs. Shown is a generic scheme for obtaining RASSLs via directed molecular evolution. In brief, a large library of randomly mutated GPCRs is obtained by error-prone PCR and used to efficiently transform the appropriate yeast strain. Yeast with functional GPCRs is grown in histidine-deficient medium in the presence of the inert ligand (in this case clozapine-N-oxide, CNO), and surviving colonies are expanded and characterized pharmacologically. GPCRs with the appropriate pharmacological profiles are subjected to iterative rounds of additional mutagenesis and selection until the ideal RASSL is obtained. Candidate RASSLs are subjected to growth assays in the presence and absence of candidate ligands to screen out those with elevated levels of constitutive activity. Typically several candidate inert ligands are used in the initial screens to determine which are most suitable for directed molecular evolution and then one or more chosen for further testing. The final choice of the candidate ligand is based on its potency and drug-like properties.

**Table 1**

## Commonly used RASSLs

Name	Alternative names: major versions	Signaling notes	Agonist and antagonists (relative affinities in nM)	In vivo phenotypes
hRO-i	Ro1 <sup>5,10</sup> : human kappa opioid receptor with delta opioid extracellular loop, and N-terminal FLAG epitope tag  hRO3-i (RO3 or Rog) <sup>36</sup> : same as Ro1, but with point mutation and N-terminal GFP tag	G <sub>i</sub> signaling, with constitutive signaling in heart, but not no apparent constitutive signaling in cultured cells	Agonists  Spiradoline (low nM) Salvinorin A (low nM)  Antagonist:  Nor-binaltorphimine-dihydrochloride (Nor-BNI) (low nM)	Cardiac, neurological, sweet taste, bitter taste, bone. See Figure 1.
hRS-s	Rs1 <sup>16,20,21</sup> : human serotonin 4 receptor with D100A mutation with N-terminal FLAG epitope tag  hRS2-s (Rs2) <sup>20</sup> : has N-terminal GFP tag	G <sub>s</sub> -signaling, with high level of constitutive activity	Agonist  RS67333, RS39604, Cisapride, ML10375, GR113808 (all nM)  Antagonist None known	Massive increase in bone formation
hRMC-s	RM1 <sup>19</sup> : human melanocortin 4 receptor with point mutations	G <sub>s</sub> -signaling constitutive signaling essential for native receptor function	Antagonist	None known
hRMD-q	DREADD hM3D <sup>8</sup> : human M <sub>3</sub> muscarinic receptor with point mutations	G <sub>q</sub> signaling	None known  Agonist  CNO (low nM)  Antagonist  Atropine (reduced affinity vs. WT; high nM)	None known
hRMD-i	DREADD hM4D <sup>8</sup> : human M <sub>4</sub> muscarinic receptor with point mutations M <sub>2</sub> receptor RASSL is also Gi coupled	Gi signaling	Agonist  CNO (low nM)  Antagonist  Atropine (reduced affinity vs. WT; high nM)	Inhibits electrical signaling in brain slices
rRMD-s	DREADD RASSL2: rat M <sub>3</sub> receptor with point mutations and intracellular loops from the turkey •1-AR	G <sub>s</sub> signaling	Agonist  CNO (low nM)  Antagonist	None known



Name	Alternative names: major versions	Signaling notes	Agonist and antagonists (relative affinities in nM)	In vivo phenotypes
			Atropine (reduced affinity vs. WT; high nM)	

This table only includes RASSLs that are actively used in transgenic animals and have a commercially available ligand with low side effects. A uniform RASSL naming system is used. For instance hRMD-q stands for: h=human, R=RASSL, M=Muscarinic, D=DREADD, q=signaling via G<sub>q</sub>. The shortest possible name is used. For the parent RASSL we do not add a number but numbers can be added, to indicate versions. For instance hRO3-i, is a GFP tagged version of hRO-i.